miR-22在儿童急性B淋巴细胞白血病中的表达及临床意义

目的探讨miR-22在儿童急性B淋巴细胞白血病(B-ALL)中的表达及临床意义。方法收集B-ALL患儿30例,以非恶性疾病或非血液病患儿10例为对照组。采集骨髓标本,提取RNA,实时荧光定量PCR方法检测miR-22的表达,并计算miR-22相对表达量。结果 miR-22相对表达量B-ALL患儿组显著低于对照组(P=0.001);治疗前显著低于治疗第33天及治疗第12周(P值分别为0.005和0.001);治疗第33天显著低于治疗第12周(P=0.012);10岁以上组显著低于10岁以下组(P=0.001);低危组显著高于中危组(P=0.007)及高危组(P=0.001);中危组与高危组比较差异无显著性(P=0.589)。结论 miR-22在儿童B-ALL中很可能存在抑癌作用。

Expression and clinical significance of miR-22 in childhood B-cell acute lymphoblastic leukemia

Objective To investigate the expression and clinical significance of microRNA-22(miR-22) in childhood B-cell acute lymphoblastic leukemia(B-ALL).Methods Bone marrow samples were collected from 30 children with B-ALL and 10 children with nonhematologic malignancies.RT-PCR was performed to detect the expression levels of miR-22 in mononuclear cells.Results The relative expression levels of miR-22 in ALL samples were significantly lower than those in control group(P=0.001);the relative expression levels of miR-22 in newly diagnosed samples were lower than those in Day 33 and Week 12 samples respectively(P=0.005 and P=0.001);besides,the miR-22 expression levels in Day 33 samples were lower than those in week 12 samples(P=0.012).The relative expression levels of miR-22 in children with more than 10 years old were significantly lower than those in children under 10 years old(P=0.001).The miR-22 expression levels in low-risk group were higher than those in moderate-risk and high-risk groups respectively(P=0.007 and P=0.001),and there was no difference between moderate-risk and high-risk groups(P=0.589).Conclusions MiR-22 is likely to have anti-tumor effect in childhood B-ALL.